We have used biochemistry, molecular & cell biology and in vivo models to identify potential biopharmaceuticals and utilized a novel screening procedure for protein candidates amenable to therapeutic manipulation. Our lead biopharmaceutical is Leptin, an adipocyte hormone thought to be controling energy homeostasis, as a replacement therapy in elderly and Alzheimer’s disease (AD) patients (patent pending). In addition, we have identified a novel protein-protein interaction in a subset of familial cases of early onset AD. This abnormal interaction between mutated Presenilin with CLIP-170 is linked to higher Abeta levels, a small peptide believed to be the culprit of the disease pathology. Disruption of this interaction in vitro can lower Abeta production and we plan to test this further.
Loading web traffic statistics. Please wait...
Recent Updates |
|---|
| Neurotez has been added to the Ecosystem. |
Leave a Reply